{"nctId":"NCT01732822","briefTitle":"A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease","startDateStruct":{"date":"2012-12-04","type":"ACTUAL"},"conditions":["Peripheral Artery Disease"],"count":13885,"armGroups":[{"label":"Ticagrelor","type":"EXPERIMENTAL","interventionNames":["Drug: Ticagrelor"]},{"label":"Clopidogrel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Clopidogrel"]}],"interventions":[{"name":"Ticagrelor","otherNames":["Brilinta/Brilique"]},{"name":"Clopidogrel","otherNames":["Plavix"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and Female patients 50 years old or older Symptomatic peripheral artery disease\n\nExclusion Criteria:\n\n* Patients needing dual anti-platlet drug treatment before start of study Planned revascularisation or amputation\n* Patients with known bleeding disorders\n* Patients with a history of intracranial bleed\n* Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke","description":"Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"751","spread":null},{"groupId":"OG001","value":"740","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite of CV Death, MI, Ischemic Stroke, and ALI","description":"Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"839","spread":null},{"groupId":"OG001","value":"833","spread":null}]}]}]},{"type":"SECONDARY","title":"CV Death","description":"Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"363","spread":null},{"groupId":"OG001","value":"343","spread":null}]}]}]},{"type":"SECONDARY","title":"MI","description":"Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"349","spread":null},{"groupId":"OG001","value":"334","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Mortality","description":"Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"628","spread":null},{"groupId":"OG001","value":"635","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)","description":"Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"766","spread":null},{"groupId":"OG001","value":"759","spread":null}]}]}]},{"type":"SECONDARY","title":"ALI","description":"Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]}]},{"type":"SECONDARY","title":"Lower Extremity Revascularization","description":"Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"846","spread":null},{"groupId":"OG001","value":"892","spread":null}]}]}]},{"type":"SECONDARY","title":"Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])","description":"Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1211","spread":null},{"groupId":"OG001","value":"1250","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Net Clinical Benefit (Composite of CV Death/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)","description":"Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"789","spread":null},{"groupId":"OG001","value":"786","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)","description":"Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"983","spread":null},{"groupId":"OG001","value":"992","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/Fatal Bleeding/Intracranial Bleeding)","description":"Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1119","spread":null},{"groupId":"OG001","value":"1140","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/TIMI Major Bleeding)","description":"Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1183","spread":null},{"groupId":"OG001","value":"1199","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Non-CV Death","description":"Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"250","spread":null},{"groupId":"OG001","value":"272","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Changes in Fontaine Stage","description":"Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage.\n\nStage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"775","spread":null},{"groupId":"OG001","value":"683","spread":null},{"groupId":"OG002","value":"171","spread":null},{"groupId":"OG003","value":"15","spread":null},{"groupId":"OG004","value":"26","spread":null},{"groupId":"OG005","value":"743","spread":null},{"groupId":"OG006","value":"723","spread":null},{"groupId":"OG007","value":"198","spread":null},{"groupId":"OG008","value":"33","spread":null},{"groupId":"OG009","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":null},{"groupId":"OG001","value":"1948","spread":null},{"groupId":"OG002","value":"560","spread":null},{"groupId":"OG003","value":"41","spread":null},{"groupId":"OG004","value":"28","spread":null},{"groupId":"OG005","value":"230","spread":null},{"groupId":"OG006","value":"1956","spread":null},{"groupId":"OG007","value":"557","spread":null},{"groupId":"OG008","value":"33","spread":null},{"groupId":"OG009","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"269","spread":null},{"groupId":"OG002","value":"469","spread":null},{"groupId":"OG003","value":"39","spread":null},{"groupId":"OG004","value":"19","spread":null},{"groupId":"OG005","value":"56","spread":null},{"groupId":"OG006","value":"311","spread":null},{"groupId":"OG007","value":"450","spread":null},{"groupId":"OG008","value":"38","spread":null},{"groupId":"OG009","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"31","spread":null},{"groupId":"OG004","value":"7","spread":null},{"groupId":"OG005","value":"9","spread":null},{"groupId":"OG006","value":"15","spread":null},{"groupId":"OG007","value":"23","spread":null},{"groupId":"OG008","value":"23","spread":null},{"groupId":"OG009","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"13","spread":null},{"groupId":"OG005","value":"4","spread":null},{"groupId":"OG006","value":"7","spread":null},{"groupId":"OG007","value":"10","spread":null},{"groupId":"OG008","value":"5","spread":null},{"groupId":"OG009","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"248","spread":null},{"groupId":"OG001","value":"743","spread":null},{"groupId":"OG002","value":"403","spread":null},{"groupId":"OG003","value":"59","spread":null},{"groupId":"OG004","value":"47","spread":null},{"groupId":"OG005","value":"250","spread":null},{"groupId":"OG006","value":"724","spread":null},{"groupId":"OG007","value":"370","spread":null},{"groupId":"OG008","value":"60","spread":null},{"groupId":"OG009","value":"45","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Changes in Rutherford Classification","description":"Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification.\n\nCategory 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.\n\nCategory 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"775","spread":null},{"groupId":"OG001","value":"683","spread":null},{"groupId":"OG002","value":"171","spread":null},{"groupId":"OG003","value":"15","spread":null},{"groupId":"OG004","value":"23","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"743","spread":null},{"groupId":"OG007","value":"723","spread":null},{"groupId":"OG008","value":"198","spread":null},{"groupId":"OG009","value":"33","spread":null},{"groupId":"OG010","value":"13","spread":null},{"groupId":"OG011","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":null},{"groupId":"OG001","value":"1948","spread":null},{"groupId":"OG002","value":"560","spread":null},{"groupId":"OG003","value":"41","spread":null},{"groupId":"OG004","value":"23","spread":null},{"groupId":"OG005","value":"5","spread":null},{"groupId":"OG006","value":"230","spread":null},{"groupId":"OG007","value":"1956","spread":null},{"groupId":"OG008","value":"557","spread":null},{"groupId":"OG009","value":"33","spread":null},{"groupId":"OG010","value":"18","spread":null},{"groupId":"OG011","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"269","spread":null},{"groupId":"OG002","value":"469","spread":null},{"groupId":"OG003","value":"39","spread":null},{"groupId":"OG004","value":"13","spread":null},{"groupId":"OG005","value":"6","spread":null},{"groupId":"OG006","value":"56","spread":null},{"groupId":"OG007","value":"311","spread":null},{"groupId":"OG008","value":"450","spread":null},{"groupId":"OG009","value":"38","spread":null},{"groupId":"OG010","value":"12","spread":null},{"groupId":"OG011","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"31","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"9","spread":null},{"groupId":"OG007","value":"15","spread":null},{"groupId":"OG008","value":"23","spread":null},{"groupId":"OG009","value":"23","spread":null},{"groupId":"OG010","value":"11","spread":null},{"groupId":"OG011","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"11","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"6","spread":null},{"groupId":"OG008","value":"6","spread":null},{"groupId":"OG009","value":"4","spread":null},{"groupId":"OG010","value":"12","spread":null},{"groupId":"OG011","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"1","spread":null},{"groupId":"OG008","value":"4","spread":null},{"groupId":"OG009","value":"1","spread":null},{"groupId":"OG010","value":"0","spread":null},{"groupId":"OG011","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"248","spread":null},{"groupId":"OG001","value":"743","spread":null},{"groupId":"OG002","value":"403","spread":null},{"groupId":"OG003","value":"59","spread":null},{"groupId":"OG004","value":"33","spread":null},{"groupId":"OG005","value":"14","spread":null},{"groupId":"OG006","value":"250","spread":null},{"groupId":"OG007","value":"724","spread":null},{"groupId":"OG008","value":"370","spread":null},{"groupId":"OG009","value":"60","spread":null},{"groupId":"OG010","value":"34","spread":null},{"groupId":"OG011","value":"11","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in ABI/TBI From Baseline","description":"Change in ankle brachial index (ABI) / toe brachial index (TBI).\n\nAnkle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD):\n\nNormal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: \\<0.4\n\nToe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used:\n\nNormal: \\>0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: \\<0.35 and toe pressure 40 mmHg Severe: \\<0.35 and toe pressure \\< 30 mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.016","spread":"0.136"},{"groupId":"OG001","value":"0.011","spread":"0.134"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.022","spread":"0.167"},{"groupId":"OG001","value":"0.016","spread":"0.167"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.050","spread":"0.132"},{"groupId":"OG001","value":"0.036","spread":"0.137"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.059","spread":"0.115"},{"groupId":"OG001","value":"-0.065","spread":"0.304"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Any Amputation Caused by PAD","description":"Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"208","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Major Amputation Caused by PAD","description":"Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"CV-related Hospitalization","description":"Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1312","spread":null},{"groupId":"OG001","value":"1314","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"TIMI Major Bleeding Events","description":"Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"TIMI Major or Minor Bleeding Events","description":"Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"193","spread":null},{"groupId":"OG001","value":"175","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"PLATO Major Bleeding Events","description":"Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":null},{"groupId":"OG001","value":"188","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Premature Permanent Discontinuation of Study Drug Due to Any Bleeding Event","description":"Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1788,"n":6932},"commonTop":["Haemorrhage","Dyspnoea"]}}}